Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there.

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

Research teams across the country are now building on this homegrown innovation to expand the potential of RNA vaccines ...

The US Department of Health and Human Services announced that the government will invest $176 million in Moderna to expedite the creation of a pandemic influenza vaccine.

Moderna stock and other vaccine makers are under pressure after ... Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming ...

As a result, Moderna's shares have suffered, falling more than 90% since their peak in 2021. Now let's consider where Moderna will be a few years from now. The company recently said it aims to ...

Moderna could face suspension from Britain’s pharmaceutical trade body following a string of breaches of the regulatory code. The Covid vaccine maker is due to be audited by the Prescription ...